Phaseline

Companies › Lyell Immunopharma

Lyell Immunopharma: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rondecabtagene autoleucel (ronde-cel)
Dual-targeting CAR T-cell therapy targeting CD19 and CD20
CD19, CD20Phase 3Large B-cell Lymphoma; Relapsed Non-Hodgkin LymphomaDec 2028
LYL273
CAR-T cell therapy (autologous T cells with chimeric antigen receptor)
–Phase 1Colorectal CancerJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05319314LYL273Phase 1Colorectal CancerOncologyJun 2028
NCT05826535Rondecabtagene autoleucel (ronde-cel)Phase 1Relapsed Non-Hodgkin LymphomaOncologyDec 2028
NCT07188558Rondecabtagene autoleucel (ronde-cel)Phase 3Large B-cell LymphomaOncologyDec 2029

From the company's SEC filings

Cash and short-term investments of $177m on 2026-09-30; operating cash outflow about $144m a year; runway about 15 months at that burn, to Dec 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (1) CD20 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech AstraZeneca Allogene Therapeutics Miltenyi Biomedicine Roche Amgen Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology

Companies built like this

Kura Oncology ALX Oncology Immuneering ADC Therapeutics Eikon Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.